NOVO — Juni 2025
-
Altimmune's incretin can't make good on fibrosis improvement promises https://firstwordpharma.com/story/5976630
-
Novo Nordisk har i den forgangne uge igen været et af de helt store samtaleemner på ProInvestor.com. Denne gang er det en droppet aftale med Hims & Hers, der fik aktiekursen til atter at droppe. Efterfulgt af en nyhed, der fik kursen lidt tilbage på sporet, nemlig et samarbejde med Weight Watchers. Så handler denne ugekommentar også om Gubra og udbytte, og om hvorvidt Zealand Pharma burde gøre det samme. Kort video: https://proinvestor.com/boards/127044
-
Novo Nordisk, Eli Lilly: "Skildpadden og Haren" https://proinvestor.com/boards/127050
-
Innovent's Lilly-partnered obesity asset wins approval in China https://firstwordpharma.com/story/5976911
-
Novo Nordisk: Fra darling til investorskepsis på 12 måneder https://proinvestor.com/boards/127061
-
Novo får ny konkurrent på fedmemarkedet i Kina https://proinvestor.com/investornyt/1334510/novo-far-ny-konkurrent-pa-fedmemarkedet-i-kina
-
I aften på tv3 - the Ozempic revolution https://www.tvguide.dk/programmer/tv3/2025-06-30/21:30/big-shot-the-ozempic-revolution
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind